In his Q3 statement, the CEO of PMD Solutions, Myles Murray, maintains his prediction of achieving cash flow positivity on an ARR basis at the end of 2024 and an ARR of SEK 260 mio. in 2026. This is of course positive, but the share reaction speaks for itself. With a less than convincing performance over the past months, we...
AcuCort AB is in the commercialization phase after launching Zeqmelit® on September 1st, and AcuCort AB is following its business plan to now expand into bigger European markets and into the US.
As with all companies in our portfolio, LSIF has had an ongoing dialogue with AcuCort since our initial investment, and the dialogue has strengthened our...
It is with great pleasure we can announce that Jan Poulsen, CEO of Life Science Invest Fund (LSIF) has been elected as chairman of the nomination committee. Lipidor AB is in phase III with APK02 which can significantly improve the lives of patients with psoriasis. The phase III result is expected towards end of Q1 2025 and will by a...
Life Science Invest Fund (LSIF) is pleased to announce, that we participate as the largest guarantor in the rights issue announced by SciBase this morning. We see SciBase as a compelling case with the Nevisense platform being a groundbreaking product for skin cancer detection and with a strong management team and large owners, who show great...
Acarix has today announced the members of the nomination committee, and LSIF is pleased to be represented by Jan Poulsen and to continue the important work from last year in securing the best possible competences on the board to be nominated at the AGM 2025.
SenzaGen has released the Q3 report showing an encouraging and solid performance. We are pleased to see revenue grow by 31% YoY and with OPEX under control. A high rate of recurring sales, increasing cross selling activity and the addition of 31 new customers in 2024 so far holds promise for continued growth. We also note the progress in...
LSIF acts as lead guarantor in BiBBInstruments AB rights issue
It is with pleasure that we can announce, that LSIF is acting as lead guarantor in the rights issue announced by BiBBInstruments AB on Friday 8th November. LSIF has agreed to be sole guarantor in the top guarantee with the aim of becoming a shareholder in BiBBInstruments AB....
Being the second largest shareholder in AcuCort AB, LSIF has this week accepted an invitation to join the nomination committee. We look forward to contributing with our insight and network in the preparation of the decisions to be taken at the 2025 General Assembly at this very important time for Acucort entering the commercial phase.
Prostatype Genomics AB has issued two interesting press releases this week. The first is regarding submission of application for Medicare reimbursement which confirms to us, that Prostatype Genomics AB so far is living up to the ambitious time schedule laid out regarding laying the foundation for entering the US market on a bigger scale.
The second...
Acarix has announced a subscription rate of 96.2% for the TO3 warrant. Acarix will receive approximately SEK 22.6 million before issuance costs which we estimate will bring the company well into H2 2025. At LSIF we are pleased to see this strong support from the shareholders. LSIF is by far the largest subscriber in this round, and LSIF also...